Search PubMedSearch

PubMed · 3132660

Posttransfusion hepatitis: a persistent problem.

Abstract

Between 1977-84 the reported frequency of clinically evident posttransfusion hepatitis has halved both nationally and in the Auckland region. This is mainly due to a decrease in the frequency of posttransfusion hepatitis B coincident with widespread introduction of sensitive screening tests for HBsAg. About half the cases of transfusion induced hepatitis are now classified as non A non B hepatitis. A further fall in the reported frequency of posttransfusion hepatitis occurred in 1985-86. Possible strategies to further reduce the low frequency of posttransfusion hepatitis in New Zealand are discussed. Although the problem of clinical posttransfusion hepatitis B or non B appears small, the need to report all such cases and to utilise blood and blood products with care is emphasised.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A M Ramirez, D G Woodfield. 1987-10-28. Posttransfusion hepatitis: a persistent problem.. https://pubmed.ncbi.nlm.nih.gov/3132660/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Current status of interferon alpha in the treatment of chronic hepatitis B.

Interferon alpha is the only available therapy for patients with chronic hepatitis B. With interferon alpha 3-15 MU thrice weekly or 5 MU daily during 3-6 months one-third of the patients achieve seroconversion of HBeAg and HBV-DNA together with normalization of aminotransferases and slight improvement of histology. Loss of HBsAg is reported in a minority of responders during treatment, but increases during follow-up. Patients with baseline alanine aminotransferase of at least twice the upper limit of normal and low HBV-DNA concentration achieve the best response rates. HIV-positive patients with low CD4 counts and Asians are poor responders. As side-effects influenza-like symptoms are experienced by almost all patients. Mild leukopenia, thrombocytopenia and decreased hairgrowth are frequently reported. Severe depression, depersonalization and psychosis are reported in a small number of patients but tend to be poorly recognized in some studies. The decision whether dose reduction is indicated seems strongly related to the opinion of the investigator. Although long-term effects on the occurrence of cirrhosis and the development of hepatocellular carcinoma are not available yet, the achieved results are promising.

Hepatitis B